GlassScriptPhysician profile
Richard Ellington
NPI 1205879632
$9,800.65
in general payments reported to CMS, 2019-2025
30 companies · $2,439 in 2025
The $2,439 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $315 · 2021: $906 · 2022: $1,039 · 2023: $1,828 · 2024: $2,283 · 2025: $2,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,551.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,882.38 | 2019-2025 | |
| Janssen Biotech, INC. | $1,500.53 | 2020-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,421.05 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $799.94 | 2019-2025 | |
| Gilead Sciences, INC. | $563.01 | 2019-2025 | Livdelzi, Epclusa |
| Phathom Pharmaceuticals, INC. | $349.11 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $313.04 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $223.19 | 2024-2025 | |
| Qol Medical, LLC | $198.24 | 2021-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $178.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Ucb, INC. | $158.89 | 2019-2020 | |
| Olympus America INC. | $146.77 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $144.15 | 2024-2025 | Iqirvo, Bylvay |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.93 | 2021-2024 | Trulance |
| Lilly USA, LLC | $121.82 | 2024-2025 | Omvoh |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $96.05 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $94.21 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.02 | 2023 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $53.63 | 2024-2025 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $53.25 | 2022 | |
| Alnylam Pharmaceuticals INC. | $47.94 | 2025 | Givlaari |
| Daiichi Sankyo INC. | $47.07 | 2024 | Injectafer |
| Celgene Corporation | $38.35 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $32.48 | 2019 | |
| Amgen INC. | $23.77 | 2021 | |
| Mylan Institutional INC. | $21.27 | 2023 | Hulio |
| Ferring Pharmaceuticals INC. | $21.16 | 2023 | Rebyota |
| Novo Nordisk INC | $17.03 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $16.52 | 2023 | |
| Allergan, INC. | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ellington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.